| http://dbpedia.org/ontology/abstract
|
Centanafadine (INN) (former developmental … Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.icates it is in Phase III clinical trials.
|
| http://dbpedia.org/ontology/casNumber
|
924012-43-1
|
| http://dbpedia.org/ontology/fdaUniiCode
|
D2A6T4UH9C
|
| http://dbpedia.org/ontology/kegg
|
D10697
|
| http://dbpedia.org/ontology/pubchem
|
16095349
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Centanafadine.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://www.neurovance.com/wp-content/uploads/2014/05/Press_Release_Neurovance_EB-1020_Data_050714.pdf%7Caccess-date=14 +
, http://adisinsight.springer.com/drugs/800035830 +
|
| http://dbpedia.org/ontology/wikiPageID
|
48554101
|
| http://dbpedia.org/ontology/wikiPageLength
|
4974
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1120769856
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Serotonin-norepinephrine-dopamine_reuptake_inhibitor +
, http://dbpedia.org/resource/Tesofensine +
, http://dbpedia.org/resource/Dopamine +
, http://dbpedia.org/resource/Drug_development +
, http://dbpedia.org/resource/Reuptake +
, http://dbpedia.org/resource/Amitifadine +
, http://dbpedia.org/resource/DOV-216%2C303 +
, http://dbpedia.org/resource/Attention-deficit_hyperactivity_disorder +
, http://dbpedia.org/resource/Euthymics_Bioscience +
, http://dbpedia.org/resource/Serotonin +
, http://dbpedia.org/resource/Category:Nitrogen_heterocycles +
, http://dbpedia.org/resource/Bicifadine +
, http://dbpedia.org/resource/International_Nonproprietary_Name +
, http://dbpedia.org/resource/Category:Cyclopropanes +
, http://dbpedia.org/resource/Category:Stimulants +
, http://dbpedia.org/resource/Category:Serotonin%E2%80%93norepinephrine%E2%80%93dopamine_reuptake_inhibitors +
, http://dbpedia.org/resource/Category:2-Naphthyl_compounds +
, http://dbpedia.org/resource/Norepinephrine +
, http://dbpedia.org/resource/DOV_Pharmaceutical +
, http://dbpedia.org/resource/Dasotraline +
|
| http://dbpedia.org/property/c
|
15
|
| http://dbpedia.org/property/casNumber
|
924012
|
| http://dbpedia.org/property/chemspiderid
|
17253639
|
| http://dbpedia.org/property/h
|
15
|
| http://dbpedia.org/property/iupacName
|
-1
|
| http://dbpedia.org/property/kegg
|
D10697
|
| http://dbpedia.org/property/legalUs
|
Investigational New Drug
|
| http://dbpedia.org/property/n
|
1
|
| http://dbpedia.org/property/pubchem
|
16095349
|
| http://dbpedia.org/property/smiles
|
C1=C[C@@]34C[C@@H]3CNC4
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
HKHCSWPSUSWGLI-CABCVRRESA-N
|
| http://dbpedia.org/property/unii
|
D2A6T4UH9C
|
| http://dbpedia.org/property/width
|
180
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Monoamine_reuptake_inhibitors +
, http://dbpedia.org/resource/Template:Abbrlink +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Keggcite +
, http://dbpedia.org/resource/Template:Nervous-system-drug-stub +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Nitrogen_heterocycles +
, http://dbpedia.org/resource/Category:Cyclopropanes +
, http://dbpedia.org/resource/Category:2-Naphthyl_compounds +
, http://dbpedia.org/resource/Category:Stimulants +
, http://dbpedia.org/resource/Category:Serotonin%E2%80%93norepinephrine%E2%80%93dopamine_reuptake_inhibitors +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Inhibitor +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Centanafadine?oldid=1120769856&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Centanafadine.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Centanafadine +
|
| owl:sameAs |
https://global.dbpedia.org/id/2YwrE +
, http://yago-knowledge.org/resource/Centanafadine +
, http://dbpedia.org/resource/Centanafadine +
, http://www.wikidata.org/entity/Q27276010 +
|
| rdf:type |
http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/Drug +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/ontology/ChemicalSubstance +
|
| rdfs:comment |
Centanafadine (INN) (former developmental … Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.icates it is in Phase III clinical trials.
|
| rdfs:label |
Centanafadine
|
